Inhaled Well toleratedLow risk of adverse effects
Systemic Poorly toleratedHigh risk of adverse effects
Pulmocide has developed a range of inhaled anti-infectives
These target the site of infection in the lung with minimal systemic exposure
The small molecules accumulate in the lung for sustained treatment
We are developing novel, potent first-in-class anti-infective agents for delivery by inhaled administration for life-threatening lower respiratory infections.